Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 24
Phase 41

Trial Status

Completed6

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT03915912Not ApplicableCompleted
Mindfulness Meditation in Glioma Patients
Malignant Glioma
PrincipalinvestigatorStart date: 2019-04-11
NCT02363933Phase 4Completed
Perampanel in Seizure Patients With Primary Glial Brain Tumors
Brain Tumor, Primary
PrincipalinvestigatorStart date: 2015-04-07
NCT00979017Phase 2Completed
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Glioblastoma MultiformeGliosarcoma
Principalinvestigator
NCT01113398Phase 2Completed
AMG 102 and Avastin for Recurrent Malignant Glioma
Glioblastoma MultiformeGliosarcoma
Principalinvestigator
NCT01303835Phase 2Completed
Low Dose Naltrexone for Glioma Patients
Malignant Glioma
Principalinvestigator

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Lou Affronti, DNP, RN, MHSc, ANP

Duke University

Moderately Similar
1 trials

Shared therapeutic areas:

GliomaNauseaVomiting

Worked with same sponsors:

Katy PetersMerck Sharp & Dohme LLC
Collaborated on 1 trial
Similarity Score34%

Mary Lou Affronti, DNP ANP MHSc

Duke University

Related
1 trials

Shared therapeutic areas:

Glioblastoma MultiformeGliosarcoma

Worked with same sponsors:

AmgenKaty Peters
Collaborated on 1 trial
Similarity Score24%

Steven Chmura, MD

University of Chicago

Related
5 trials

Shared therapeutic areas:

Glioblastoma MultiformeGliomaMalignant Glioma
Similarity Score13%

Thomas Kaley, MD

Memorial Sloan Kettering Cancer Center

Related
9 trials

Shared therapeutic areas:

Malignant GliomaGliomaGliosarcoma

Worked with same sponsors:

Genentech, Inc.Merck Sharp & Dohme LLC
Similarity Score13%

Kevin A camphausen, M.D.

National Cancer Institute (NCI)

Related
17 trials

Shared therapeutic areas:

GliosarcomaGlioblastoma MultiformeMalignant Glioma
Similarity Score13%

Annick Desjardins, MD, FRCPC

Duke University

Related
9 trials

Shared therapeutic areas:

Malignant GliomaGliosarcomaGlioblastoma Multiforme

Worked with same sponsors:

AmgenDuke University+1 more
Similarity Score13%

Sean Grimm, MD

Northwestern University

Related
2 trials

Shared therapeutic areas:

Glioblastoma MultiformeMalignant Glioma
Similarity Score9%

Roya Yumul, MD, PhD

Cedars-Sinai Medical Center

Related
9 trials

Shared therapeutic areas:

NauseaVomiting
Similarity Score9%

Gustavo Leone

Medical University of South Carolina, Hollings Cancer Center

Related
12 trials

Shared therapeutic areas:

Glioblastoma MultiformeGlioma

Worked with same sponsors:

Genentech, Inc.
Similarity Score9%

Jeffrey Raizer, MD

Northwestern University

Related
8 trials

Shared therapeutic areas:

Malignant GliomaGlioblastoma Multiforme
Similarity Score9%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT03915912Not ApplicablePrincipalInvestigator

Mindfulness Meditation in Glioma Patients

Malignant Glioma
Completed
NCT02363933Phase 4PrincipalInvestigator

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Brain Tumor, Primary
Completed
NCT01450826Phase 2PrincipalInvestigator

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

GliomaNauseaVomiting
Completed
NCT00979017Phase 2PrincipalInvestigator

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Glioblastoma MultiformeGliosarcoma
Completed
NCT01113398Phase 2PrincipalInvestigator

AMG 102 and Avastin for Recurrent Malignant Glioma

Glioblastoma MultiformeGliosarcoma
Completed
NCT01303835Phase 2PrincipalInvestigator

Low Dose Naltrexone for Glioma Patients

Malignant Glioma
Completed

All 6 trials loaded